Baxter International Inc. 2003 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2003. Baxter International Inc. is a global medical products and services company operating in three primary segments: Medication Delivery (IV solutions, specialty products), BioScience (biopharmaceuticals, blood collection), and Renal (kidney disease treatment). The company manufactures in 29 countries and sells in over 100 countries, with approximately 50% of revenues generated outside the United States. As of December 31, 2003, the company employed approximately 51,300 people.
Key Financial Metrics
Specific consolidated revenue, net income, and cash flow figures for 2003 are incorporated by reference from the Annual Report to Stockholders and are not explicitly detailed in the provided text. However, the following specific financial data points are available:
- Research and Development (R&D): $553 million in 2003 (compared to $501 million in 2002).
- Capital Expenditures: $789 million in 2003 (including $110 million for equipment placed with customers).
- Market Capitalization: Approximately $15.5 billion as of June 30, 2003 (based on a $26.00 share price).
- Shares Outstanding: 612,327,565 shares as of March 1, 2004.
- Reserves (Schedule II):
- Allowance for doubtful accounts: $66 million (end of period).
- Inventory reserves: $121 million (end of period).
- Litigation reserves: $211 million (end of period).
- Deferred tax asset valuation allowance: $151 million (end of period).
Material Changes and Operational Highlights
The filing highlights several strategic and operational developments for 2003:
- Product Launches and Approvals:
- BioScience: FDA approval for ADVATE (recombinant Factor VIII) and launch of ARALAST (alpha-1 antitrypsin). Launch of the ALYX Component Collection System.
- Medication Delivery: Introduction of bar-code technology for IV solutions to reduce medication errors. Launch of the SYNDEO patient-controlled analgesia pump and FDA approval for PREMASOL.
- Renal: Launch of EXTRANEAL (icodextrin solution) in the U.S. and Japan. Introduction of the ARENA HD instrument and EXELTRA dialyzers.
- Leadership Change: Chairman and CEO Harry M. Jansen Kraemer, Jr. announced his decision to resign in January 2004, agreeing to serve until a successor is named.
- Customer Concentration: Sales to members of Premier Purchasing Partners L.P. represented 8.3% of consolidated net sales in 2003, down from 8.9% in 2002 and 10.1% in 2001.
Guidance, Risks, and Contingencies
Legal Proceedings and Contingencies: The company faces significant litigation risks, though management believes reserves are adequate and no single charge would materially affect the consolidated financial position. Key areas include:
- Mammary Implant Litigation: 106 lawsuits pending as of Dec 31, 2003. A federal government appeal regarding reimbursement for medical care was remanded to the district court in September 2003.
- Plasma-Based Therapies: Ongoing claims regarding HIV/Hepatitis C infections from factor concentrates (late 1970s-mid 1980s). Settlements are ongoing in the U.S. and Japan. Immuno International AG contingent liabilities are covered by a $20 million withholding from the purchase price.
- Althane Dialyzers: Civil lawsuits and government investigations regarding patient injuries/deaths. Criminal investigations in Spain and Croatia were closed without action against the company.
- Thimerosal/Vaccines: 143 lawsuits filed regarding autism/attention deficit disorders linked to vaccines containing Thimerosal (formerly manufactured by acquired North American Vaccine, Inc.).
- SEC Inquiry: In July 2003, the SEC requested documents regarding revisions to 2003 growth and earnings forecasts. Baxter is cooperating fully.
- Competition and Pricing: Intense competition from global and domestic companies, consolidation of customers (GPOs/IDNs), and government price controls are creating pricing pressure.
- Regulatory: Extensive regulation by the FDA and international agencies regarding product safety, manufacturing, and labeling.
- Currency: Fluctuations in foreign currencies, particularly a strengthening U.S. dollar, could negatively impact international sales and earnings.
Investor Verification Checklist
- Verify the specific revised earnings per share (EPS) figures announced in the December 23, 2003 Form 8-K referenced in the filing.
- Review the Annual Report to Stockholders (incorporated by reference) for detailed segment revenue, profit margins, and cash flow statements, as these are not explicitly listed in the 10-K text provided.
- Monitor the status of the SEC inquiry regarding 2003 forecast revisions and the outcome of the Althane dialyzer government investigations.
- Assess the impact of the CEO transition on strategic execution and future leadership stability.
- Track the resolution of litigation reserves, particularly regarding mammary implants and plasma-based therapies, to ensure reserves remain adequate.